Dr. Altman on Gilteritinib in Patients With Relapsed/Refractory AML

Jessica K. Altman, MD
Published: Wednesday, Aug 23, 2017



Jessica K. Altman, MD, associate professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern Medicine, discusses an early-phase study of gilteritinib in FLT3-mutation–positive patients with acute myeloid leukemia (AML).

This phase I/II study, which was recently published in Lancet Oncology, investigated gilteritinib in these relapsed/refractory patients with AML, Altman explains. Patients were not required to have FLT3 mutations, but researchers did enrich the patient cohort to have a larger number of patients with FLT3 mutations. The dose-escalation study had a primary endpoint of determining the maximum-tolerated dose, as well as assessing the safety, tolerability, associated toxicities, and anti-leukemic activity of the drug. The phase II component explored the efficacy of the agent.

Results showed that the maximum-tolerated dose was 300 mg once daily and common side effects seen were fatigue, diarrhea, elevation of liver function test, she adds.


Jessica K. Altman, MD, associate professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern Medicine, discusses an early-phase study of gilteritinib in FLT3-mutation–positive patients with acute myeloid leukemia (AML).

This phase I/II study, which was recently published in Lancet Oncology, investigated gilteritinib in these relapsed/refractory patients with AML, Altman explains. Patients were not required to have FLT3 mutations, but researchers did enrich the patient cohort to have a larger number of patients with FLT3 mutations. The dose-escalation study had a primary endpoint of determining the maximum-tolerated dose, as well as assessing the safety, tolerability, associated toxicities, and anti-leukemic activity of the drug. The phase II component explored the efficacy of the agent.

Results showed that the maximum-tolerated dose was 300 mg once daily and common side effects seen were fatigue, diarrhea, elevation of liver function test, she adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x